LR is a 36 y/o, 61kg female with a history of asthma and HTN seen in your clinic. You see that she is taking Nordette 28, a combined oral contraceptive containing 30mcg of estradiol and 0.15mg of levonorgestrel. She is generally pleased with her contraceptive which she has been taking successfully for years. What modification is advised based on the information you have about LR?

Combined oral contraceptives (COCs) such as Ethinyl estradiol and levonorgestrel (Nordette) are commonly used for long-term pregnancy prevention and work by inhibiting ovulation and altering cervical mucus. When evaluating contraceptive therapy, clinicians consider efficacy, tolerability, comorbid conditions such as hypertension and asthma, and risk factors for thromboembolism. In patients who are stable, satisfied, and not experiencing adverse effects, continuation of the current regimen is often appropriate. Unnecessary switching can increase the risk of breakthrough symptoms and nonadherence. Rationale: A. Switching to an ultra-low estrogen dose such as Aviane 28 is not necessary because the patient is already tolerating her current regimen well without complications. Reducing estrogen may increase the risk of breakthrough bleeding and does not provide a significant safety advantage in a stable, healthy patient. Changes should only be made if there are clinical concerns or adverse effects. B. No therapy modification is appropriate because the patient is stable on Ethinyl estradiol and levonorgestrel (Nordette) with good tolerance and effective contraceptive control. She has no reported side effects or contraindications such as uncontrolled hypertension or estrogen-related complications. Maintaining a well-tolerated and effective regimen supports adherence and minimizes unnecessary medication changes. C. Switching to a contraceptive patch such as Xulane is not indicated because there is no evidence of failure or intolerance to the current oral contraceptive. Additionally, transdermal estrogen delivery can result in higher systemic estrogen exposure compared to oral forms, which may increase thromboembolic risk. This makes it an unnecessary escalation in this stable patient. D. Switching to a drospirenone-containing pill such as Ocella is also not indicated because she is not experiencing androgen-related side effects or fluid retention. While drospirenone has anti-mineralocorticoid properties, it also carries a higher risk of thromboembolism compared to some older progestins. Without a specific clinical indication, changing therapy is not warranted.